FMO5

Across TCGA pan-cancer cohorts, FMO5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FMO5 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FMO5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FMO5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where FMO5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.539	0.260	<.001	106	view →
CCRCC	OS	Quartile	All	0.962	0.697	.002	38	view →
GBM	OS	Median	All	1.000	0.117	.024	9	view →
UCEC	DFS	Median	III,IV	0.252	1.000	.036	8	view →
LUAD	OS	Quartile	III,IV	0.848	0.387	.015	3	view →
LSCC	DFS	Median	All	0.912	0.957	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FMO5–PDAC (DFS)

Open the PDAC breakdown →